comparemela.com

Latest Breaking News On - Grzegorz nowakowski - Page 1 : comparemela.com

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

Expert hematologist-oncologist Grzegorz Nowakowski, MD, reviews data from the 5-year analysis of the L-MIND study combining tafasitamab with lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.

Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL

Curis Announces Date for the 1st Symposium on IRAK4 in Cancer

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.